The U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has recommended approval of Sanofi’s New Drug Application…
Category: Insulin
Another insulin coming to us in 2016 is Lilly’s new basal insulin, Basaglar – a form of insulin glargine (which you may recognize if you’re familiar with Lantus). FDA approved it just this week after a patent dispute was finally resolved with Sanofi.
The U.S. FDA approved Basaglar (insulin glargine injection), the newest diabetes treatment from the Lilly-Boehringer Ingelheim diabetes…
The U.S. FDA approved Basaglar (insulin glargine injection), the newest diabetes treatment from the Lilly-Boehringer Ingelheim diabetes…
The first improvement over Lantus, according to Hobbs, is simply the length of time the insulin lasts. While Lantus lasts up to 24 hours per dose “with no pronounced peak,” Tresiba lasts considerably longer.
More than two years after dealing Novo Nordisk a surprising setback, the U.S. Food and Drug Administration has approved Tresiba (insulin degludec…
The penny-sized patch is embedded with more than one hundred tiny needles, each about the width and length of an eyelash. Those needles in turn are loaded with microscopic storage units containing insulin and glucose-sensing enzymes that trigger a release of insulin when blood sugar levels go past a certain level.
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; as an endocrinologist (for ten years he ran a clinical practice focused on patients of all ages with diabetes); as an executive at a pharmaceutical company working to develop new treatments (he’s worked at Novo Nordisk since 2004); and as a parent (one of his six sons was diagnosed with type 1 at age five)
The European Commission has granted Sanofi marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), for the treatment of type 1 and type 2 diabetes mellitus in adults. Toujeo is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile.
Researchers at MIT successfully tested an engineered “smart insulin” on mice that reacts to blood sugar levels.
“To make insulin that is…